Diagnosis and treatment of systemic and localized scleroderma

Expert Review of Dermatology

Volumn 6, Issue 3, 2011, Pages 287-302

  Khanna, Dhanita ^a  

^a Sahara Hospital   (India)

Author keywords

criteria; drugs; localized scleroderma; morphea; systemic sclerosis; therapy

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CARDIOLIPIN ANTIBODY; CENTROMERE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FIBRILLARIN ANTIBODY; ILOPROST; IMATINIB; KU ANTIBODY; METHOTREXATE; PENICILLAMINE; PHOSPHODIESTERASE INHIBITOR; PM SCL ANTIBODY; PROSTACYCLIN; RIBONUCLEOPROTEIN ANTIBODY; RNA POLYMERASE ANTIBODY; SILDENAFIL; SM ANTIBODY; STEROID; TADALAFIL; TH ANTIBODY; TO ANTIBODY; TOPOISOMERASE I ANTIBODY; U1 RIBONUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST;

ANTIBODY SPECIFICITY; ARTHRITIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BLOOD VESSEL INJURY; BONE MARROW TOXICITY; CAPILLAROSCOPY; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIAGNOSTIC IMAGING; DIARRHEA; DIFFUSE SCLERODERMA; DIGITAL ULCER; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ECHOCARDIOGRAPHY; EDEMA; FIBROBLAST; FIBROGENESIS; GASTROINTESTINAL TRACT; HEART DISEASE; HEMATOLOGICAL ABNORMALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMIFACIAL ATROPHY; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INFRARED PHOTOGRAPHY; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER TOXICITY; LOCALIZED SCLERODERMA; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; LUNG FUNCTION TEST; MORPHEA; MUSCLE CRAMP; MYASTHENIA GRAVIS; MYOCARDITIS; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PEMPHIGUS; PERIPHERAL EDEMA; PHOTOTHERAPY; POLYARTHRITIS; POLYMYOSITIS; PRIORITY JOURNAL; PROTEINURIA; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SCLERODERMA RENAL CRISIS; SIDE EFFECT; SKIN BIOPSY; SKIN ULCER; SKINFOLD; SYMPATHECTOMY; SYSTEMIC SCLEROSIS; VASODILATATION;

EID: 79958226304     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/edm.11.26     Document Type: Review

References (78)

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 23(5), 581-590 (1980).
2. Lonzetti LS, Joyal F, Raynauld JP, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum. 44(3), 735-736 (2001). (Pubitemid 32234635)
3. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynauds phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 58(12), 3902-3912 (2008).
4. Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann. Rheum. Dis. 70(3), 476-481(2011).
5. Cron RQ, Swetter SM. Scleredema revisited. A poststreptococcal complication. Clin. Pediatr. (Phila.) 33(10), 606-610 (1994).
6. Colvert T, Emery JL, Graham JT. Scleredema with haematuria and a raised antistreptolysin titre - recovery with cortisone: case report. Arch. Dis. Child. 37, 103-105 (1962).
7. Avouac J, Walker U, Tyndall A, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J. Rheumatol. 37(7), 1488-1501 (2010).
8. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res. Ther. 5(2), 80-93 (2003). (Pubitemid 36849754)
9. Varga J, Rudnicka L, Uitto J. Connective tissue alterations in systemic sclerosis (review). Clin. Dermatol. 12, 387-396 (1994). (Pubitemid 24266924)
10. Weihrauch TR, Korting GW. Manometric assessment of oesophageal involvement in progressive systemic sclerosis, morphoea and Raynauds disease. Br. J. Dermatol. 107, 325-332 (1982). (Pubitemid 12051483)
11. Davidson A, Russell C, Littlejohn GO. Assessment of esophageal abnormalities in progressive systemic sclerosis using radionuclide transit. J. Rheumatol. 12, 472-477 (1985). (Pubitemid 15004942)
12. Candell-Riera J, Armandans-Gil L, Simeon CP. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum. 39, 1138-1145 (1996). (Pubitemid 26240226)
13. Alton E, Turner-Warwick M. Lung involvement in scleroderma. In: Systemic Sclerosis: Scleroderma. Jayson MIV, Black CM (Eds). John Wiley & Sons, Chichester, UK, 181-205 (1988).
14. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum. 28, 759-767 (1985). (Pubitemid 15027329)
15. Clements PJ, Furst DE, Campion DS. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum. 21, 62-71 (1978). (Pubitemid 9127954)
16. Steen VD. Scleroderma renal crisis. Rheum. Dis. Clin. North. Am. 22, 861-878 (1996). (Pubitemid 26396055)
17. Keogh A, Strange G, Kotlyar E, et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern. Med. J. 41(3), 235-244 (2011).
18. Nihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 103(2), 109-115 (2010).
19. Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynauds phenomenon and scleroderma. Rheum. Dis. Clin. North. Am. 29, 275-291 (2003).
20. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium channel blockers for Raynauds phenomenon in systemic sclerosis. Arthritis Rheum. 44(8), 1841-1847 (2001). (Pubitemid 32758232)
21. Pope J, Fenlon D, Thompson A, et al. Prazosin for Raynauds phenomenon in progressive systemic sclerosis. Cochrane Database Syst. Rev. 2, CD000956 (2000).
22. Wise RA, Wigley FM, White B, et al. Efficacy and tolerability of a selective a(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum. 50(12), 3994-4001 (2004). (Pubitemid 39643948)
23. Milio G, Corrado E, Genova C, et al. Iloprost treatment in patients with Raynauds phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology 45(8), 999-1004 (2006). (Pubitemid 44283056)
24. Caramaschi P, Volpe A, Tinazzi I, Bambara LM, Carletto A, Biasi D. Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. Rheumatol. Int. 27(2), 203-205 (2006). (Pubitemid 46088283)
25. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. 132, 425-434 (2000). (Pubitemid 30149039)
26. Budev MM, Minai OA, Arroliga AC. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension. Drugs Today (Barc.) 40(3), 225-234 (2004). (Pubitemid 38596225)
27. Maddison P. Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition. Rheumatology (Oxford) 41(9), 965-971 (2002).
28. Penn H, Denton CP. Diagnosis, management and prevention of scleroderma renal disease. Curr. Opin. Rheumatol. 20(6), 692-696 (2008).
29. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynauds phenomenon and scleroderma: clinical and biochemical findings in a fifteen week, randomized, parallel-group, controlled trial. Arthritis Rheum. 42, 2646-2655 (1999). (Pubitemid 30327186)
30. Ramani GV, Park MH. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. Drug Des. Devel. Ther. 25(4), 61-70 (2010).
31. Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann. Rheum. Dis. 69(8), 1475-1478 (2010).
32. Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynauds phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 49(12), 2420-2428 (2010
33. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann. Rheum. Dis. 65(10), 1336-1340 (2006). (Pubitemid 44620443)
34. Korn JH, Mayes M, Matucci-Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 50, 3985-3993 (2004). (Pubitemid 39643947)
35. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 70(1), 32-38 (2011).
36. Seibold JR, Denton CP, Furst DE, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 62(7), 2101-2108 (2010).
37. Distler JH, Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford) 47(Suppl. 5), v10-v11 (2008).
38. de Andrade JA, Thannickal VJ. Innovative approaches to the therapy of fibrosis. Curr. Opin. Rheumatol. 21(6), 649-655 (2009).
39. Blank N, Max R, Lorenz HM. The role of DMARDs in systemic sclerosis therapy. Rheumatology (Oxford) 45 (Suppl. 3), iii42-iii44 (2006). (Pubitemid 44446778)
40. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 42, 1194-1203 (1999). (Pubitemid 29268956)
41. Derk CT, Huaman G, Jimenez SA. A retrospective randomly selected cohort study of d-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br. J. Dermatol. 158(5), 1063-1068 (2008). (Pubitemid 351521424)
42. Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J. Rheumatol. 36(2), 323-329 (2009).
43. Filaci G, Cutolo M, Basso M, et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology 40, 1431-1432 (2001). (Pubitemid 34065384)
44. Miniati I, Valentini G, Cerinic MM. Cyclophosphamide in systemic sclerosis: still in search of a real life scenario Arthritis Res. Ther. 11(1), 103 (2009).
45. Milanetti F, Bucha J, Testori A, Burt RK. Autologous hematopoietic stem cell transplantation for systemic sclerosis. Curr. Stem Cell Res. Ther. 6(1), 16-28 (2011).
46. Wasserman A, Brahn E. Systemic sclerosis: bilateral improvement of Raynauds phenomenon with unilateral digital sympathectomy. Semin. Arthritis Rheum. 40(2), 137-146 (2010).
47. Denton CP. Renal manifestations of systemic sclerosis - clinical features and outcome assessment. Rheumatology (Oxford) 47(Suppl. 5) v54-v56 (2008).
48. Mathai SC, Hassoun PM. Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr. Opin. Rheumatol. 21(6), 642-648 (2009).
49. Hatano M, Yao A, Shiga T, Kinugawa K, Hirata Y, Nagai R. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int. Heart J. 51(4), 272-276 (2010).
50. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131(6), 1917-1928 (2007). (Pubitemid 46981654)
51. Goldin J, Elashoff R, Kim HJ, et al. Treatment of scleroderma- interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high resolution CT scan than placebo: findings from the scleroderma lung study. Chest 136(5), 1333-1340 (2009
52. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655-2666 (2006).
53. Sabnani I, Zucker MJ, Rosenstein ED, et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 48(1), 49-52 (2009).
54. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin. Proc. 70(11), 1068-1076 (1995).
55. Holland KE, Steffes B, Nocton JJ, Schwabe MJ, Jacobson RD, Drolet BA. Linear scleroderma en coup de sabre with associated neurologic abnormalities. Pediatrics 117(1), e132-e136 (2006). (Pubitemid 46050511)
56. Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 45(5), 614-620 (2006).
57. Marzano AV, Menni S, Parodi A, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur. J. Dermatol. 13(2), 171-176 (2003). (Pubitemid 36428363)
58. el-Azhary RA, Aponte CC, Nelson AM, Weaver AL, Homburger HA. Antihistone antibodies in linear scleroderma variants. Int. J. Dermatol. 45(11), 1296-1299 (2006). (Pubitemid 44688021)
59. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase IIa autoantibodies in localized scleroderma. Arthritis Rheum. 50(1), 227-232 (2004). (Pubitemid 38084308)
60. Zulian F, Meneghesso D, Grisan E, et al. A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology (Oxford) 46(5), 856-860 (2007). (Pubitemid 47064263)
61. Martini G, Murray KJ, Howell KJ, et al. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology (Oxford) 41(10), 1178-1182 (2002). (Pubitemid 35203548)
62. Weibel L, Howell KJ, Visentin MT, et al. Laser Doppler flowmetry for assessing localized scleroderma in children. Arthritis Rheum. 56(10), 3489-3495 (2007). (Pubitemid 47585445)
63. Li SC, Liebling MS, Ramji FG, et al. Sonographic evaluation of pediatric localized scleroderma: preliminary disease assessment measures. Pediatr. Rheumatol. Online J. 27(8), 14 (2010).
64. Horger M, Fierlbeck G, Kuemmerle-Deschner J, et al. MRI findings in deep and generalized morphea (localized scleroderma). Am. J. Roentgenol. 190(1), 32-39 (2008).
65. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch. Dermatol. 138, 99-105 (2002). (Pubitemid 34056240)
66. Rocken M, Ghoreschi K. Morphea and lichen sclerosus. In: Dermatology (2nd Edition). Bolognia JL, Jorizzo JL, Rapini RP (Eds). Mosby, NY, USA, 1469-1483 (2008).
67. Alarcon-Segovia D, Ramos-Niembro F, Ibanez de Kasep G, Alcocer J, Tamayo RP. Long term evaluation of colchicine in the treatment of scleroderma. J. Rheumatol. 6(6), 705-712 (1979). (Pubitemid 10178207)
68. Taveira M, Selores M, Costa V, Massa A. Generalized morphea and lichen sclerosus et atrophicus successfully treated with sulphasalazine. J. Eur. Acad. Dermatol. Venereol. 12(3), 283-284 (1999). (Pubitemid 29372007)
69. Brownell I, Soter NA, Franks AG Jr. Familial linear scleroderma (en coup de sabre) responsive to antimalarials and narrowband ultraviolet B therapy. Dermatol. Online J. 13(1), 11 (2007).
70. Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology (Oxford) 48(11), 1410-1413 (2009)
71. Mancuso G, Berdondini RM. Topical tacrolimus in the treatment of localized scleroderma. Eur. J. Dermatol. 13(6), 590-592 (2003). (Pubitemid 38030805)
72. Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L. First cases series on the use of imiquimod for morphoea. Br. J. Dermatol. 153(4), 815-820 (2005). (Pubitemid 41415912)
73. Hunzelmann N, Anders S, Fierlbeck G, et al. Double-blind, placebo-controlled study of intralesional interferon g for the treatment of localized scleroderma. J. Am. Acad. Dermatol. 36(3 Pt 1), 433-435 (1997). (Pubitemid 27131967)
74. Sunderkötter C, Kuhn A, Hunzelmann N, Beissert S. Phototherapy: a promising treatment option for skin sclerosis in scleroderma? Rheumatology (Oxford) 45(Suppl. 3), iii52-iii54 (2006). (Pubitemid 44446781)
75. Elst EF, Van Suijlekom-Smit LW, Oranje AP. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr. Dermatol. 16(1), 53-58 (1999). (Pubitemid 29102635)
76. Kreuter A, Gambichler T, Avermaete A, et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr. Dermatol. 18(3), 241-245 (2001). (Pubitemid 32567879)
77. Eisen D, Alster TS. Use of a 585 nm pulsed dye laser for the treatment of morphea. Dermatol. Surg. 28(7), 615-616 (2002). (Pubitemid 34816047)
78. Roh MR, Jung JY, Chung KY. Autologous fat transplantation for depressed linear scleroderma-induced facial atrophic scars. Dermatol. Surg. 34(12), 1659-1665 (2008).